Sigilon is a biotechnology company developing functional cures for patients with chronic diseases. It develops Shielded Living Therapeutics, or SLTx, platform, which combines cell engineering with innovations in biocompatible materials and enables Sigilon's product candidates to produce a range of therapeutic molecules that may be missing or deficient, such as proteins, antibodies, and hormones. The SLTx platform is designed to improve the management of chronic diseases by overcoming the significant limitations of cell and gene therapies and the drawbacks of the current standard of care biologic-based therapies.
|HQ||Cambridge, MA, US||Map|
Revenue (FY, 2019)
Revenue growth (FY, 2018 - FY, 2019), %
Net income (FY, 2019)
EBIT (FY, 2019)
Market capitalization (4-Jun-2021)
Closing stock price (4-Jun-2021)
Sigilon has 552 Twitter Followers. The number of followers has increased 2.6% month over month and increased 6.8% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Sigilon founded?
Sigilon was founded in 2015.
Who are Sigilon key executives?
Sigilon's key executives are Rogerio Vivaldi, Hozefa Bandukwala and Deya Corzo.
How many employees does Sigilon have?
Sigilon has 96 employees.
What is Sigilon revenue?
Latest Sigilon annual revenue is $14.2 m.
What is Sigilon revenue per employee?
Latest Sigilon revenue per employee is $147.4 k.
Who are Sigilon competitors?
Competitors of Sigilon include Confo Therapeutics, Pandion Therapeutics and Rubius Therapeutics.
Where is Sigilon headquarters?
Sigilon headquarters is located at 100 Binney St #600, Cambridge.
Where are Sigilon offices?
Sigilon has an office in Cambridge.
How many offices does Sigilon have?
Sigilon has 1 office.
Receive alerts for 300+ data fields across thousands of companies